Insmed Provides Clinical Update on Phase 2b CEDAR Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. USO
6. TSLA
7. META
8. COHR
9. AMD
10. AMC

Go back to Insmed Provides Clinical Update on Phase 2b CEDAR Study
INSMED (NASDAQ: INSM) Delayed: 121.00 --0 (-0%)
Previous Close $121.00    52 Week High $19.30 
Open $121.00    52 Week Low $9.02 
Day High $121.00    P/E N/A 
Day Low $121.00    EPS $-1.69 
Volume 101